Cayuga Biotech

Executive Summary

Cayuga Biotech is a private, preclinical-stage biotechnology company founded in 2019 and headquartered in Ithaca, New York. The company is pioneering first-in-class, small molecule therapeutics designed to harness the body's innate ability to control life-threatening hemorrhage. Its lead program focuses on addressing significant unmet needs in non-compressible bleeding and coagulation dysfunction, areas where current treatments are limited and mortality rates remain high. By targeting the body's natural hemostatic pathways, Cayuga aims to develop rapid-acting, easy-to-administer interventions that could be used in trauma, surgical, and emergency settings.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data Presentation60% success
• Q4 2026Series A Financing Closing70% success
• H1 2027IND-Enabling Studies Initiation50% success